920O Safety and efficacy of first-in-class, YAP/TEAD inhibitor, VT3989 in refractory pleural and non-pleural mesothelioma: A phase I/II study
Year: 2025
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Authors: T.A. Yap, M.D. Offin, D.J. Kwiatkowski, R. Kratzke, I. Dagogo-Jack, A.W. Tolcher, J. Desai, A. Body, M. Millward, N. Sharma, Y. Li, H.L. Kindler
Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, University of Minnesota, Massachusetts General Hospital, Peter MacCallum Cancer Centre, Monash Medical Centre, Monash Health, Linear Clinical Research, University of Chicago Medical Center
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4415939937